PHILADELPHIA — Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
"While it is established that tobacco smoke is a risk factor for nasopharyngeal carcinoma [the most common cancer arising from the upper part of the throat behind the nose and near the base of skull], its role in influencing survival of patients with established cancers is not known," said Fang-Yun Xie, M.D., professor in the Department of Radiation Oncology at the Sun Yat-sen University Cancer Center in Guangzhou, China. "We found that cigarette smoking does influence the survival of patients with nasopharyngeal carcinoma. Patients with a history of smoking, regardless of whether they ceased smoking for one or more years, have poorer survival than those who never smoked."
In the United States, about 2,900 people are expected to develop nasopharyngeal carcinoma in 2013, and about half of the people with this cancer are younger than 55 years old, according to the American Cancer Society. This cancer is more common in some parts of China.
"Our findings demonstrate the dangers of cigarette smoking in terms of the survival of patients. Hence, we strongly recommend that people, including those with nasopharyngeal carcinoma, do not smoke," said Xie.
Xie and colleagues followed 1,849 newly diagnosed nasopharyngeal carcinoma patients admitted to the Sun Yat-sen University Cancer Center between 2005 and 2007. They gathered information on smoking and drinking history, and demographics. The primary endpoint for the study was overall survival, and secondary endpoints were progression-free survival, locoregional relapse-free survival, and distant metastasis-free survival. Patients were followed for up to eight years.
During follow-up, 8 percent of the patients developed locoregional relapse, about 13 percent had their disease spread to distant organs, and 20 percent died of their disease.
The researchers found that among all nasopharyngeal carcinoma patients, those who smoked heavily were 3.3-fold more likely to die, 2.5-fold more likely to have their disease progress, and 2.7-fold more likely to have their disease spread to distant organs, compared with those who did not smoke. Both former and current smokers were impacted equally.
They also found a dose-response relationship between pack-years smoked and increase in risk of death or progression: the higher the pack-years, the lower the survival rate.
The findings were still significant in subgroup analyses and after adjusting for age, gender, drinking status, cancer subtype, tumor stage, spread of the disease, status of Epstein-Barr virus infection (which can cause this cancer), radiation techniques, and chemotherapy regimens.
"Previous studies have found that cancer patients resume smoking after treatment because of a higher perceived difficulty of quitting, and lower perceptions of their cancer-related risk," said Xie. "Our finding that cigarette smoking lowers the chance of survival for nasopharyngeal carcinoma patients, with a dose-response relationship, is a key fact that the general audience should keep in mind."
This study was funded by the National Natural Science Foundation of China and the Science Foundation of Key Hospital Clinical Program of Ministry of Health of China. The authors have declared no conflicts of interest.
Follow the AACR on Twitter: @AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.